Peripartum Management of Gestational Diabetes Using a Digital Health Care Service: A Pilot, Randomized Controlled Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sung, Ji-Hee | - |
dc.contributor.author | Lee, Da Young | - |
dc.contributor.author | Min, Kyoung Pil | - |
dc.contributor.author | Park, Cheol-Young | - |
dc.date.accessioned | 2021-09-01T01:22:06Z | - |
dc.date.available | 2021-09-01T01:22:06Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-11 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/62057 | - |
dc.description.abstract | Purpose: The prevalence of gestational diabetes mellitus (GDM) is increasing, and multifaceted interventions are effective in the management of GDM. This study aimed to develop and evaluate a model for the management of GDM with the use of mobile health care. Methods: This was a prospective, randomized controlled pilot study. A total of 21 patients who were diagnosed with GDM during 24-28 weeks of gestation were randomly divided into a conventional management (CM) group (n = 10) and a mobile management (MM) group (n = 11). The CM group received conventional GDM management and could freely use the mobile health care application. The MM group received mobile health care services, including tailored mobile coaching. After delivery, obstetric outcomes were collected, and 75-g oral glucose tolerance test was performed at 5-12 weeks postpartum. Findings: Baseline characteristics, including glycosylated hemoglobin (HbA(1c)), were not significantly different between the 2 groups. No statistically significant differences were found in rates between the 2 groups for (1) neonate large for gestational age and (2) cesarean section at the time of delivery. No significant difference was found in HbA(1c) between the 2 groups after delivery. However, postpartum homeostatic model assessment insulin resistance, body mass index, weight, and percentage of body fat were significantly lower in the MM group. (C) 2019 Elsevier Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.subject | OBESITY | - |
dc.subject | MELLITUS | - |
dc.subject | GLUCOSE | - |
dc.subject | TRIAL | - |
dc.subject | RISK | - |
dc.title | Peripartum Management of Gestational Diabetes Using a Digital Health Care Service: A Pilot, Randomized Controlled Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Da Young | - |
dc.identifier.doi | 10.1016/j.clinthera.2019.09.005 | - |
dc.identifier.scopusid | 2-s2.0-85072779697 | - |
dc.identifier.wosid | 000503107700019 | - |
dc.identifier.bibliographicCitation | CLINICAL THERAPEUTICS, v.41, no.11, pp.2426 - 2434 | - |
dc.relation.isPartOf | CLINICAL THERAPEUTICS | - |
dc.citation.title | CLINICAL THERAPEUTICS | - |
dc.citation.volume | 41 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 2426 | - |
dc.citation.endPage | 2434 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | OBESITY | - |
dc.subject.keywordPlus | MELLITUS | - |
dc.subject.keywordPlus | GLUCOSE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordAuthor | weight | - |
dc.subject.keywordAuthor | gestational diabetes | - |
dc.subject.keywordAuthor | insulin resistance | - |
dc.subject.keywordAuthor | mobile health care | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.